16 September 2026 editorial review · Item
Century Therapeutics CNTY-813 (Allo-Evasion 5.0 iPSC islets): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: Century's company and ADA evidence is preclinical. Q4 2026 IND and second-half 2027 first-data guidance remain plans. Future October presentations were not counted as completed results; no human CNTY-813 outcomes were located.
- Primary publication/regulatory sources checked or consulted: NEJMc2604408.
- Programme/sponsor/conference source boundary: New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026 (manufacturer); Century Therapeutics Reports First Quarter 2026 Financial Results and Business Updates (manufacturer); Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D Clinical & Research Congress 2026 (manufacturer); Century Therapeutics pipeline — CNTY-813, beta islet cells (Allo-Evasion 5.0) (manufacturer).